Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?

× No keyword cloud information.

5 in total

1. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.

Authors: Aida Laurinaviciene; Darius Dasevicius; Valerijus Ostapenko; Sonata Jarmalaite; Juozas Lazutka; Arvydas Laurinavicius
Journal: Diagn Pathol Date: 2011-09-23 Impact factor: 2.644

2. Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer.

Authors: Kyeongmee Park; Sehwan Han; Jung-Yeon Kim; Hyun-Jung Kim; Ji Eun Kwon; Geumhee Gwak
Journal: J Breast Cancer Date: 2011-12-27 Impact factor: 3.588

3. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.

Authors: Mieke R Van Bockstal; Marie Colombe Agahozo; Ronald van Marion; Peggy N Atmodimedjo; Hein F B M Sleddens; Winand N M Dinjens; Lindy L Visser; Esther H Lips; Jelle Wesseling; Carolien H M van Deurzen
Journal: Mol Oncol Date: 2020-03-05 Impact factor: 6.603

4. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.

Authors: George Fountzilas; Urania Dafni; Mattheos Bobos; Vassiliki Kotoula; Anna Batistatou; Ioannis Xanthakis; Christos Papadimitriou; Ioannis Kostopoulos; Triantafillia Koletsa; Eleftheria Tsolaki; Despina Televantou; Eleni Timotheadou; Angelos Koutras; George Klouvas; Epaminontas Samantas; Nikolaos Pisanidis; Charisios Karanikiotis; Ioanna Sfakianaki; Nicholas Pavlidis; Helen Gogas; Helena Linardou; Konstantine T Kalogeras; Dimitrios Pectasides; Meletios A Dimopoulos
Journal: BMC Cancer Date: 2013-03-28 Impact factor: 4.430

5. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

Authors: Edith A Perez; Michael F Press; Amylou C Dueck; Robert B Jenkins; Chungyeul Kim; Beiyun Chen; Ivonne Villalobos; Soonmyung Paik; Marc Buyse; Anne E Wiktor; Reid Meyer; Melanie Finnigan; Joanne Zujewski; Mona Shing; Howard M Stern; Wilma L Lingle; Monica M Reinholz; Dennis J Slamon
Journal: Breast Cancer Res Treat Date: 2013-02-19 Impact factor: 4.872

5 in total